New drug combo shows promise in Hard-to-Treat breast cancer
Disease control
Completed
This study tested a new drug called taselisib combined with standard anti-HER2 therapies in 68 people with advanced HER2+ breast cancer. The goal was to find the safest dose and see if the combination could shrink tumors or slow the disease. While not a cure, the approach aims to…
Phase: PHASE1 • Sponsor: Otto Metzger, MD • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC